利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

28 条记录 (耗时 0.011 秒)

    Antibiotic product, use and formulation thereof
    1.
    发明申请
    Antibiotic product, use and formulation thereof 有权
    抗生素产品，其用途和配方

    公开(公告)号：US20020136764A1

    公开(公告)日：2002-09-26

    申请号：US10027609

    申请日：2001-12-20

    发明人： Edward M. Rudnic ,  James D. Isbister ,  Donald J. Treacy JR. ,  Sandra E. Wassink

    IPC分类号： A61K009/52

    CPC分类号： A61K9/2081 ,  A61K9/1635 ,  A61K9/1652 ,  A61K9/5026 ,  A61K9/5084 ,  A61K31/00 ,  A61K31/4164 ,  A61K31/43 ,  A61K31/7048 ,  A61K45/06 ,  A61K2300/00

    摘要： An antibiotic product, in particular a betalactam such as cephalosporin (in particular cefuroxime and/or cefpodoxime) or a penicillin (in particular axmoxicillin or dicloxacillin) is comprised of at least three dosages forms, each of which has a different release profile, with the Cmax for the antibiotic product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosage form, as well as two or more delayed release dosage forms, with each of the dosage forms having a different release profile, wherein each reaches a Cmax at different times.

    摘要翻译： 一种抗生素产品，特别是诸如头孢菌素（特别是头孢呋辛和/或头孢泊肟）或青霉素（特别是阿莫西林或双氯西林）的β-内酰胺包含至少三种剂型，每种剂型具有不同的释放特性，其中 抗生素产品的C max在少于约12小时内达到。 在一个实施方案中，存在立即释放剂型以及两种或更多种延迟释放剂型，其中每种剂型具有不同的释放曲线，其中各个在不同时间达到C max。

    Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent
    2.
    发明申请
    Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent 失效
    用于抗心律不齐剂的脉动递送的口服药物剂型

    公开(公告)号：US20020098232A1

    公开(公告)日：2002-07-25

    申请号：US09929838

    申请日：2001-08-14

    发明人： Kamal K. Midha ,  Mark Hirsh ,  Whe-Yong Lo

    IPC分类号： A61K009/52 ,  A61K009/26 ,  A61K009/24

    CPC分类号： A61K9/5084 ,  A61K9/2081 ,  A61K9/209

    摘要： Novel pharmaceutical dosage forms provide for pulsatile delivery of an antiarrhythmic agent that releases the drug in spaced apart nullpulses.null The dosage forms are comprised of first, second and optional third dosage units, with each dosage unit having a different drug release profile. The dosage forms may comprise capsules housing compressed tablets or drug-containing beads, granules, or particles or may comprise a single tablet with the first, second and optional third dosage units incorporated therein, or a nullcoated corenull dosage form. Methods of treatment using the pharmaceutical dosage forms are provided as well.

    摘要翻译： 新颖的药物剂型提供抗心律失常药物的脉动递送，其以间隔开的“脉冲”释放药物。 剂型由第一，第二和任选的第三剂量单位组成，每个剂量单位具有不同的药物释放曲线。 剂型可以包含容纳压制片剂或药物珠粒，颗粒剂或颗粒的胶囊，或者可以包含其中掺入第一，第二和任选的第三剂量单位的单一片剂或“包衣核心”剂型。 还提供了使用药物剂型的治疗方法。

    Sustained-release preparation
    5.
    发明申请
    Sustained-release preparation 有权
    缓释制剂

    公开(公告)号：US20020031545A1

    公开(公告)日：2002-03-14

    申请号：US09520150

    申请日：2000-03-07

    发明人： Hiroaki Okada ,  Yayoi Douken

    IPC分类号： A61K009/52

    CPC分类号： A61K9/1647 ,  A61K38/09 ,  Y10S514/963 ,  Y10S514/965

    摘要： Disclosed is a sustained-release preparation comprising 1) a polymer of lactic acid having a weight-average molecular weight of about 25,000 to about 60,000 and 2) a physiologically active substance, and which releases the physiologically active substance over a period of at least about 5 months; the sustained-release preparation shows an almost continuous zero order release of the physiologically active substance over a period of as long as about 5 months.

    摘要翻译： 公开了一种持续释放制剂，其包含1）重均分子量为约25,000至约60,000的乳酸聚合物和2）生理活性物质，并且在至少约1周的时间内释放生理活性物质 5个月; 持续释放制剂在长达约5个月的时间内显示生理活性物质几乎连续的零级释放。

    Sustained release drug delivery devices with coated drug cores
    9.
    发明申请
    Sustained release drug delivery devices with coated drug cores 审中-公开
    持续释放药物输送装置，涂有药物核心

    公开(公告)号：US20020086051A1

    公开(公告)日：2002-07-04

    申请号：US10034707

    申请日：2001-12-27

    发明人： Santos Viscasillas

    IPC分类号： A61K009/48 ,  A61K009/52

    CPC分类号： A61K9/0051

    摘要： The present invention is directed to an improved sustained release drug delivery device comprising a drug core comprising a polymer coated inner core and an impermeable cup or reservoir.

    摘要翻译： 本发明涉及一种改进的缓释药物递送装置，其包括药物核心，其包含聚合物涂覆的内芯和不可渗透的杯子或储存器。

    Extended release formulation
    10.
    发明申请
    Extended release formulation 有权
    延长释放配方

    公开(公告)号：US20020025339A1

    公开(公告)日：2002-02-28

    申请号：US09950965

    申请日：2001-09-12

    申请人： American Home Products Corporation

    发明人： Deborah M. Sherman ,  John C. Clark ,  John U. Lamer ,  Steven A. White

    IPC分类号： A61K009/52

    CPC分类号： A61K31/137 ,  A61K9/1652 ,  A61K9/5047 ,  Y10S514/962

    摘要： This invention relates to a 24 hour extended release dosage formulation and unit dosage form thereof of venlafaxine hydrochloride, an antidepressant, which provides better control of blood plasma levels than conventional tablet formulations which must be administered two or more times a day and fiber provides a lower incidence of nausea and vomiting than the conventional tablets. More particularly, the invention comprises an extended release formulation of venlafaxine hydrochloride comprising a therapeutically effective amount of venlafaxine hydrochloride in spheroids comprised of venlafaxine hydrochloride, microcrystalline cellulose and, optionally, hydroxypropylmethylcellulose coated with a mixture of ethyl cellulose and hydroxypropylmethylcellulose.

    摘要翻译： 本发明涉及盐酸文拉法辛的24小时延长释放剂量制剂及其单位剂型，抗抑郁药与日常的片剂制剂相比，可提供更好的对血浆水平的控制，每天必须给药2次或更多次，而纤维提供较低的 恶心呕吐发生率高于传统药片。 更具体地说，本发明包括文拉法辛盐酸盐的延长释放制剂，其包含由盐酸文拉法辛，微晶纤维素和任选的用乙基纤维素和羟丙基甲基纤维素的混合物包被的羟丙基甲基纤维素组成的球形体中的治疗有效量的盐酸文拉法星。